Sivik Global Healthcare LLC decreased its position in Humana Inc. (NYSE:HUM – Free Report) by 14.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 15,000 shares of the insurance provider’s stock after selling 2,500 shares during the period. Humana comprises approximately 2.9% of Sivik Global Healthcare LLC’s portfolio, making the stock its 12th biggest holding. Sivik Global Healthcare LLC’s holdings in Humana were worth $6,867,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the company. Morgan Stanley increased its position in shares of Humana by 6.2% in the third quarter. Morgan Stanley now owns 2,040,896 shares of the insurance provider’s stock valued at $992,938,000 after acquiring an additional 119,760 shares during the period. Ameriprise Financial Inc. raised its position in Humana by 35.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock valued at $741,409,000 after purchasing an additional 402,559 shares during the last quarter. Northern Trust Corp lifted its holdings in Humana by 5.1% in the 3rd quarter. Northern Trust Corp now owns 1,327,489 shares of the insurance provider’s stock worth $645,850,000 after buying an additional 64,245 shares during the period. Invesco Ltd. grew its position in shares of Humana by 1.4% in the 3rd quarter. Invesco Ltd. now owns 965,488 shares of the insurance provider’s stock worth $469,729,000 after buying an additional 13,670 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Humana by 39.3% during the third quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock valued at $331,743,000 after buying an additional 192,546 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.
Humana Stock Performance
NYSE:HUM traded down $1.06 during trading hours on Tuesday, reaching $302.09. The company had a trading volume of 1,565,451 shares, compared to its average volume of 1,990,495. The firm has a market cap of $36.40 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 1.79 and a beta of 0.45. The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.77. The firm’s 50 day moving average price is $325.94 and its 200-day moving average price is $392.00. Humana Inc. has a 52 week low of $299.23 and a 52 week high of $541.21.
Humana Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.17%. Humana’s dividend payout ratio (DPR) is 22.04%.
Insider Buying and Selling at Humana
In related news, Director Jorge S. Mesquita acquired 545 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was bought at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the purchase, the director now owns 2,578 shares in the company, valued at approximately $946,358.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.29% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Several research firms recently weighed in on HUM. The Goldman Sachs Group cut their price target on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a report on Wednesday, April 3rd. Oppenheimer cut their price objective on Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Cantor Fitzgerald dropped their price target on Humana from $391.00 to $360.00 and set a “neutral” rating on the stock in a research report on Thursday, April 25th. Bank of America reissued a “neutral” rating and set a $342.00 price objective (down previously from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Finally, Stephens dropped their target price on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. Eleven analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $424.50.
View Our Latest Report on Humana
Humana Profile
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Articles
- Five stocks we like better than Humana
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Hilton Demonstrates Asset Light is Right for Investors
- Find and Profitably Trade Stocks at 52-Week Lows
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.